Turn Therapeutics Stock Forecast

Stock Price Forecast

The 3 analysts that cover Turn Therapeutics stock have a consensus rating of "Buy" and an average price target of $6.77, which forecasts a 28.22% increase in the stock price over the next year. The lowest target is $6.15 and the highest is $8.00.

Price Target: $6.77 (+28.22%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$6.15	$6.77	$6.15	$8.00
Change	+16.48%	+28.22%	+16.48%	+51.52%

* Price targets were last updated on Jan 13, 2026.

Analyst Ratings

The average analyst rating for Turn Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Mar '26	May '26
Strong Buy	1	1	1	1
Buy	0	0	0	0
Hold	0	0	0	0
Sell	0	0	0	0
Strong Sell	0	0	0	0
Total	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Karen Sterling Westpark Capital	Westpark Capital	Buy Initiates $6.15	Buy	Initiates	$6.15	+16.48%	Jan 13, 2026
Unknown Analyst WBB Securities No rating	WBB Securities	Buy Initiates $6.15	Buy	Initiates	$6.15	+16.48%	Jan 12, 2026
Jason Kolbert D. Boral Capital	D. Boral Capital	Buy Initiates $8	Buy	Initiates	$8	+51.52%	Dec 29, 2025

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.10

from -0.21

EPS Next Year

-0.15

from -0.10

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-
Operating Income	-4.21M	-2.31M	-1.80M	-6.36M	-3.85M
Net Income	-4.29M	-2.29M	-1.77M	-3.19M	-3.57M
EPS	-	-	-	-0.21	-0.10
Free Cash Flow	-	-2.01M	-824.22K	1.74M	-3.85M
No. Analysts	-	-	-	-	1

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.10
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-